Skeletal muscle metastasis as a first site of recurrence of cervical cancer

A case report and review of the literature

Nagisa Omokawa, MD\textsuperscript{a}, Seiji Mabuchi, MD, PhD\textsuperscript{a,\textcentering\textcopyright.}, Kana Iwai, MD\textsuperscript{a}, Naoki Kawahara, MD\textsuperscript{a}, Ryuji Kawaguchi, MD, PhD\textsuperscript{b}, Sumire Sugimoto, MD\textsuperscript{b}, Chiho Ohbayashi, MD, PhD\textsuperscript{b}, Kanya Honoki, MD, PhD\textsuperscript{c}, Akira Nagai, MD, PhD\textsuperscript{c}, Hiroshi Kobayashi, MD, PhD\textsuperscript{d}

Abstract
Rationale: Cervical cancer primarily spreads through direct invasion or via local lymphatics, and hematogenous metastasis is infrequent. Previous reports have shown that lung, liver, and bone are the organs most frequently affected by hematogenous metastasis of cervical cancer, while skeletal muscle is very rarely involved.

Patient concerns: A 75-year-old Japanese woman presented with a painful muscular mass in her right lower abdomen. Five years ago, she was treated for her International Federation of Gynecology and Obstetrics stage IB2 cervical adenocarcinoma with radical surgery plus adjuvant chemotherapy.

Diagnoses: The patient was diagnosed with isolated oblique muscle metastasis from cervical adenocarcinoma as a first site of recurrence.

Interventions: The patient was treated with salvage surgery consisting of partial resection of the oblique muscle and ilium. The tumor was completely excised with an adequate surgical margin by a partial resection of the oblique muscle and ilium.

Outcomes: The patient is currently free of disease at 10 months after the development of recurrent disease.

Lessons: We describe a rare case of isolated oblique muscle metastasis as a first site of recurrence of the International Federation of Gynecology and Obstetrics stage IB2 cervical adenocarcinoma, which was successfully treated with surgery. Although skeletal muscle metastasis is rare, this condition should be considered during the follow-up period, especially when patients complain of muscular pain with insidious progression. The present case and our literature review highlighted the possibility that loco-regional treatment may be curative for selected recurrent cervical cancer developed in skeletal muscles.

Abbreviations: CT = computed tomography, DFI = disease-free interval, FIGO = the International Federation of Gynecology and Obstetrics, MRI = magnetic resonance imaging.

Keywords: cervical cancer, metastasis, oblique muscle, treatment

1. Introduction

Cervical cancer primarily spreads by direct invasion or through the local lymphatics, and hematogenous metastasis is uncommon, with lung, liver, and bone being the most frequent sites of hematogenous metastasis.\textsuperscript{[1]} Although the skeletal muscles represent up to 50\% of the total body weight and receive a large percentage of total cardiac output, skeletal muscle metastasis is extremely rare in patients with solid malignancies, including cervical cancer, with a reported incidence of less than 1\%.\textsuperscript{[2]} Patients who present with untreated cervical cancer and skeletal muscle metastasis are diagnosed as the International Federation of Gynecology and Obstetrics (FIGO) stage IVB, and they usually also have other metastatic lesions and a dismal prognosis.\textsuperscript{[2,3]} However, in the setting of recurrent disease, it seems that skeletal muscle metastasis does not always indicate systemic disease (Table 1), and successful results of loco-regional treatment have been reported in patients with isolated skeletal muscle metastasis.\textsuperscript{[4-21]}

In this report, we describe our experience with isolated oblique muscle metastasis as a first site of recurrence of FIGO stage IB2 cervical adenocarcinoma, which was successfully treated by surgery. Moreover, based on a literature review, we also provide information about the management of skeletal muscle metastasis in cervical cancer patients in a recurrent setting.
## Table 1
Summary of reported cases with skeletal muscle metastasis as sites of recurrence of uterine cervical cancer.

| Author (yr) | Age | HIV status | FIGO stage | Histology | Initial treatment | DFI (mo) | Site of recurrence | Involved muscle | Other sites | Pain | Salvage treatment | Outcome |
|-------------|-----|------------|------------|-----------|------------------|---------|-------------------|----------------|------------|-----|------------------|---------|
| Mariya Y (1990) | 48 | Negative | IIB | SCC | RT + chem | 13 | Biceps | Lung | No | No | Chem + Palliative RT | DOD 3 mo |
| Wong BJF (1995) | 34 | Negative | IB1 | Small | S + RT | 24 | Masseter | No | No | No | Chem + Palliative RT | NA |
| Pathy S (2002) | 38 | Negative | IIB | SCC | RT | 0 | Deltoïd | No | Yes | BSC | AWD |
| Saadi I (2003) | 62 | Negative | IIB | SCC | S + RT | 60 | Psoas | No | NA | No | S + Chem + RT | NED 8 mo |
| Fernández G (2006) | 38 | Negative | IB1 | SCC | S | 76 | Intercostal | No | No | No | Chem + Palliative RT | DOD 10 mo |
| Kim HS (2008) | 64 | Negative | IIB | SCC | CCRT | 12 | Deltoïd | No | No | No | Chem + Palliative RT | NED |
| Pathy S (2008) | 50 | Negative | IIB | SCC | CCRT | 2 | Biceps | Lung | Yes | S + Chem + Palliative RT | AWD 8 mo |
| Karunanithi G (2010) | 48 | Negative | IB1 | A | S | 4 | Abdominal wall | No | Yes | S + Chem | NED 5 mo |
| Kalayci MJ (2013) | 48 | Negative | IB1 | SCC | CCRT | 6 | Oblique, iliopecto, | Abdominal wall | No | Yes | S + Chem + Palliative RT | NED 36 mo |
| Taman MO (2013) | 46 | Negative | NA | NA | CCRT | 6 | Oblique, iliopecto, | Cervix, pelvic nodes, | subcutaneous tissue | NA | NA | NA |
| Kaur M (2016) | 45 | Negative | IIB | SCC | CCRT | 12 | Parietal | No | Yes | Chem + Palliative RT | DOD |
| Skenderi F (2016) | 43 | Negative | IIB | SCC | CCRT | 24 | Intercostal | Pleura, lung | Yes | Chem + Palliative RT | DOD 8 mo |
| Varadarajan I (2017) | 51 | Negative | IIB | SCC | CCRT | 24 | Psoas | No | Yes | Chemotherapy | DOD 11 mo |
| Albuñuelos OM (2017) | 64 | Negative | IB2 | ASC | S + CCRT | 34 | Psoas | No | Yes | CCRT | NED 24 mo |
| Miyoshi A (2018) | 57 | Negative | IIB | SCC | CCRT | 26 | Latissimus dorsi | Arm pit | NA | Chem + S + RT | DOD 16 mo |
| Rodriguez J (2019) | 34 | Negative | IB2 | A | CCRT | 21 | Parietal | Kidney | No | Yes | S + RT | DOD 5 mo |
| Current study | 75 | Negative | IB2 | A | S | 62 | Oblique | No | Yes | S | NED 10 mo |

A = adenocarcinoma, ASC = adenosquamous carcinoma, AWD = alive with disease, BSC = best supportive care, CCRT = concurrent chemoradiotherapy, Chem = chemotherapy, DFI = disease-free interval, DOD = died of disease, FIGO = the International Federation of Gynecology and Obstetrics, HIV = human-immunodeficiency virus, NA = not available, NED = alive with no evidence of disease, RT = radiotherapy, S = surgery, SCC = squamous cell carcinoma, Small = small cell carcinoma.
1.1. Case report

A 70-year-old Japanese woman presented with postmenopausal vaginal bleeding. She had a history of diabetes mellitus and hepatitis C. On evaluation, she was found to have a 6 cm friable cervical mass. There was no parametrial involvement and rectal examination was normal. Pelvic magnetic resonance imaging (MRI) showed a 6 cm cervical mass limited to the uterine cervix and an enlarged pelvic lymph node (left obturator node). Biopsies of the lesion demonstrated adenocarcinoma. Computed tomography (CT) scans of the abdomen and chest showed no evidence of metastatic disease, and laboratory findings were unremarkable. A diagnosis of FIGO stage IB2 cervical cancer was made from these findings, and she underwent radical hysterectomy with bilateral salpingo-oophorectomy. Pathological examination of the surgical specimen revealed invasive serous carcinoma of the uterine cervix with right obturator lymph node metastasis (pT1b2N1M0) (Fig. 1). Deep stromal invasion and lymphovascular space involvement were also noted, but the surgical margin, fallopian tubes, and both ovaries were free of tumor. Because of the pathological risk factors, adjuvant therapy was recommended, and she received adjuvant chemotherapy with 6 cycles of carboplatin (AUC5) plus paclitaxel (175 mg/kg).

Sixty-two months after the initial operation, she presented with a painful mass in her right lower abdomen. On examination, she had a 5 cm nodular lesion in the right anterior abdominal wall close to the ilium. The mass was not mobile and was not attached to the overlying skin. Abdominal CT and pelvic MRI showed a 5 cm tumor in her right internal oblique muscle, with no radiologic evidence of other metastatic disease. MRI showed a 5 cm mass in the oblique muscle that extended to the right ilium (Fig. 2). Biopsy of the mass revealed poorly differentiated carcinoma. 2-Deoxy-2-[18F]fluoro-D-glucose position emission tomography demonstrated increased 2-deoxy-2-[18F]fluoro-D-glucose uptake by the tumor, with no evidence of other metastatic disease. Laboratory findings were unremarkable. Salvage surgery with partial resection of the oblique muscle and ilium was performed 69 months after the initial operation, and the tumor was completely excised with an adequate surgical margin (Fig. 3). The resulting abdominal wall defect was repaired using dual mesh. Pathological examination of the resected tumor revealed recurrent adenocarcinoma extending from the oblique muscle to the right pelvic wall (Fig. 1A, B). Immunohistochemically, the tumor cells were strongly positive for cytokeratin AE1/AE3 (i) and p53 (ii), but negative for estrogen receptor (iii), showing the similar immunoreactivity profile as the primary cervical tumor.

1.2. Patient consent for publication

Informed written consent was obtained from the patient for publication of this case report and accompanying images.
Figure 2. Images of the metastasis in the right oblique muscle. A, Contrast-enhanced computed tomography. B, Contrast-enhanced magnetic resonance imaging (T1-weighted). Arrows indicate a 5 x 6 cm enhancing tumor with direct involvement of the ilium. C, 2-deoxy-2-[18F]fluoro-D-glucose position emission tomography shows a hypermetabolic lesion in the right oblique muscle. Arrows indicate an oblique muscle tumor.

Figure 3. A, Appearance of the recurrent tumor in the right iliac region. B and C, Oblique muscle tumor with direct involvement of the ilium (B, intraoperative view; C, resected tumor).
2. Discussion

We presented our experience with isolated oblique muscle metastasis showing direct invasion of the ilium, which was developed as a first site of recurrence of FIGO stage IB2 cervical adenocarcinoma at 5 years after initial surgery. The patient was successfully treated by extensive surgery, including osteotomy.

The reason for the rarity of skeletal muscle metastasis of cervical cancer remains unclear, although several hypotheses have been postulated:

- contraction of skeletal muscle and constant fluctuations of intramuscular blood pressure act as mechanical barriers to tumor cell implantation;
- local production of lactic acid prevents tumor cell proliferation;
- protease inhibitors in the basement membrane of myocytes inhibit tumor cell invasion; and
- lymphocytes and natural killer cells in skeletal muscles destroy tumor cells.

Cervical cancer is the most common female cancer worldwide. However, as shown in Table 1, our comprehensive literature search found only 19 cases of skeletal muscle metastases developed as sites of recurrence in patients with cervical cancer, indicating the rarity of this condition. The abdominal wall muscles, ilioptosae, and paravertebral muscles are most commonly affected, consistent with previous reports. Importantly, of the 19 patients with skeletal muscle metastases, 11 (57.8%) had isolated disease, indicating that skeletal muscle involvement by a recurrent tumor does not necessarily indicate systemic disease.

The risk factors remain largely unknown, although previous reports have suggested that patients with human immunodeficiency virus infection or with advanced cervical cancer are at high risk of skeletal muscle metastasis. However, a correlation between such risk factors and skeletal muscle metastasis is not demonstrated in Table 1.

Pain is the most common presenting symptom in patients with skeletal muscle metastasis, and it can be helpful for diagnosis, since soft tissue sarcoma is usually painless, whereas skeletal muscle metastasis frequently presents as a painful soft tissue mass. However, as shown in Table 1, one-third (5/15) of skeletal muscle metastases are asymptomatic. While imaging modalities (contrast-enhanced CT, contrast-enhanced MRI, or 2-deoxy-2-[18F] fluoro-D-glucose position emission tomography) are useful for detecting skeletal muscle tumors, they cannot differentiate soft tissue sarcoma from skeletal muscle metastasis. Thus, suspected metastasis should be confirmed by fine needle aspiration biopsy.

Although case reports are available, there are no guidelines regarding treatment of this condition due to lack of clinical trials. As shown in Table 1, supportive care alone, chemotherapy, palliative radiotherapy, or chemotherapy following palliative radiotherapy have been tried for multiple metastases. In contrast, surgical excision or definitive radiotherapy with or without adjuvant treatment have been employed for solitary lesions.

The clinical outcome of patients with skeletal muscle metastases in a recurrent setting is generally poor (Table 1). This is at least partly due to the presence of systemic disease, and all 7 patients with no evidence of disease after salvage treatment had isolated skeletal metastasis. As would be expected, the mortality rate of recurrent cervical cancer patients with isolated skeletal muscle metastasis (18.2%; 2/11) is significantly lower than that of patients with skeletal muscle tumors as part of multiple metastases (75%; 6/8). There may also be other predictors of a favorable outcome. All patients who survived for longer than 1 year after salvage treatment for skeletal muscle metastasis underwent surgery or radiotherapy. Accordingly, the presence of disseminated tumors at diagnosis of skeletal muscle metastasis and the type of salvage treatment may be predictors of survival for this patient population. Moreover, among the 5 patients with disease-free interval (DFI) >30 months, only 1 patient (20%) died of disease progression and the mortality rate was significantly lower than among patients with DFI <30 months (7/14, mortality rate of 50%). This suggests that DFI may be a useful prognostic indicator for these patients. We consider that local treatment should be done, either surgery or radiotherapy with or without adjuvant treatment, at least for patients having an isolated tumor with a longer DFI.

In conclusion, we experienced a rare case of isolated oblique muscle metastasis as a first site of recurrence of FIGO stage IB2 cervical adenocarcinoma. Although skeletal muscle metastasis is rare, this condition should be considered during the follow-up period, especially when patients complain of muscular pain with insidious progression. The present case and our literature review highlighted the possibility that loco-regional treatment may be curative in selected recurrent cervical cancer patients with skeletal muscle metastasis. Given the rarity of this condition, we believe it is important to report individual cases so that optimal treatment can be established.

Author contributions

NO, KI and NK collected data regarding isolated recurrence using the PubMed database. NO, SM, KI, RK, KH and AN conducted surgical procedure. SS and HK made substantial contribution to conception of the study. SS and CO conducted histopathological and immunostaining procedure. SM contributed to the study design, writing manuscript, and interpretation of included clinical studies. The final version of the manuscript has been read and approved by all authors.

Conceptualization: Seiji Mabuchi, Hiroshi Kobayashi.
Data curation: Nagisa Omokawa, Seiji Mabuchi, Kana Iwai, Naoki Kawahara.
Funding acquisition: Hiroshi Kobayashi.
Investigation: Seiji Mabuchi, Sumire Sugimoto, Chiho Oobayashi, Kanya Honoki.
Methodology: Seiji Mabuchi.
Resources: Ryuji Kawaguchi, Kanya Honoki.
Supervision: Seiji Mabuchi, Ryuji Kawaguchi.
Visualization: Seiji Mabuchi, Sumire Sugimoto, Chiho Oobayashi.
Writing – original draft: Seiji Mabuchi.
Writing – review & editing: Naoki Kawahara.
References

[1] Lifshitz SG, Buchsbaum HJ. Spread of cervical carcinoma. Obstet Gynecol Annu 1977;6:341–54.
[2] Sudo A, Oghara Y, Shiokawa Y, et al. Intramuscular metastasis of carcinoma. Clin Orthop Relat Res 1993;296:213–7.
[3] Vishnoi MG, Jain A, John AR, et al. A rare case of extensive skeletal muscle metastases in adenocarcinoma cervix identified by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography scan. Indian J Nucl Med 2016;31:215–8.
[4] Mariya Y, Watanabe S, Yokoyama Y, et al. Metastasis of uterine cervical cancer to the biceps muscle of right upper arm: a report of a case. Rinsho Hoshasen 1990;35:1447–50.
[5] Wong BJ, Passy V, DiSaia P. Metastatic small cell carcinoma to the masseter muscle originating from the uterine cervix. Ear Nose Throat J 1995;74:118–21.
[6] Pathy S, Jayalakshmi S, Chander S, et al. Carcinoma cervix with metastasis to deltoid muscle. Clin Oncol (R Coll Radiol) 2002;14:447–8.
[7] Saâdi I, Hadadi K, Amaoui B, et al. Muscle metastasis of squamous cell carcinoma of the uterine cervix. Cancer Radorher 2003;7:187–9.
[8] Ferrandina G, Salutari V, Testa A, et al. Recurrence in skeletal muscle from squamous cell carcinoma of the uterine cervix: a case report and review of the literature. BMC Cancer 2006;6:169.
[9] Kim HS, Park NH, Kang SB. Rare metastases of recurrent cervical cancer to the pericardium and abdominal muscle. Arch Gynecol Obstet 2008;278:479–82.
[10] Padhi S, Banerjee S, Das S, et al. Carcinoma cervix with atypical presentation of metastatic lesion as a cyst in the right deltoid muscle. Indian J Pathol Microbiol 2008;51:450–1.
[11] Karunanithi G, Sethi P, Reddy KS, et al. Skeletal muscle metastasis from carcinoma cervix: a case report. J Gynecol Pathol 2010;21:196–8.
[12] Sil AK, Biswas B, Saha JK, et al. Unusual presentation of metastasis in adenocarcinoma cervix. J Indian Med Assoc 2012;110:649–50.
[13] Kalayci MU, Gonenc M, Yalcin O, et al. Isolated muscle metastasis of cervical cancer. J Obest Gynaecol 2013;33:641–3.
[14] Tamam MO, Mulazimoglu M, Aydan T. Subcutaneous and intramuscular metastases of cervix cancer detected with (18)F-fluoro-2-deoxyglucose positron emission tomography/computed tomography after the chemoradiation therapy. Rev Esp Med Nucl Imagen Mol 2013;32:128–9.
[15] Kausar M, Ladia DD, Matneja A, et al. Unusual skeletal muscle metastasis from carcinoma cervix. J Cancer Metastasis Treat 2016;2:67–9.
[16] Skenderi F, Chikha A, Ilisevic N, et al. Skeletal muscle metastases from squamous cell carcinoma of the cervix: report of two cases with literature review. Int J Gynecol Pathol 2017;36:95–100.
[17] Varadarajan I, Basu A, Besmer S, et al. Solitary skeletal muscle metastasis as first site of recurrence of cervical cancer: a case report. Case Rep Oncol 2017;10:694–8.
[18] Albulescu DM, Ionovici N, Moldovan HR, et al. Muscle metastases from cervical carcinoma – case report. Rom J Morphol Embryol 2017;58:545–51.
[19] Miyoshi A, Kuritani Y, Kanao S, et al. Aggressive skeletal muscle metastasis from cervical cancer invading into the spinal canal: a case report. Clin Case Rep 2019;7:361–5.
[20] Rodriguez J, Castro JC, Beltran M, et al. Simultaneous metastasis from cervical cancer to the kidney and paraspinal muscle: a case report. Cureus 2019;11:e418.
[21] Weiss L. Biomechanical destruction of cancer cells in skeletal muscle: a rate-regulator for hematogenous metastasis. Clin Exp Metastasis 1989;7:483–91.
[22] Acins García O, Fernández FA, Satué EG, et al. Metastasis of malignant neoplasms to skeletal muscle. Rev Esp Oncol 1984;31:57–67.
[23] Schwartz LB, Carcangiu ML, Bradham L, et al. Rapidly progressive squamous cell carcinoma of the cervix coexisting with human immunodeficiency virus infection: clinical opinion. Gynecol Oncol 1991;41:235–8.